Table 3:
Prevalence of polypharmacy (≥5 unique prescriptions) by age and comorbidity (n=24,804)
| Cancer Survivor (n=5,216) | Non-Cancer Control (n=19,588) | |||||
|---|---|---|---|---|---|---|
| n | weighted % | 95% CI | n | weighted % | 95% CI | |
| Age | ||||||
| 18–39 | 220 | 41.8 | 34.5–46.0 | 360 | 20.8 | 18.3–23.4 |
| 40–49 | 318 | 51.4 | 46.5–56.2 | 633 | 28.8 | 26.3–31.2 |
| 50–59 | 571 | 54.5 | 50.8–58.2 | 1622 | 41.7 | 39.6–43.8 |
| 60–69 | 885 | 67.9 | 64.6–71.1 | 2862 | 58.6 | 56.9–60.3 |
| 70–79 | 730 | 72.8 | 69.4–76.3 | 2324 | 68.3 | 66.3–70.3 |
| ≥80 | 548 | 79.1 | 75.3–82.8 | 1423 | 68.8 | 66.2–71.5 |
| Comorbidity count | ||||||
| 0 | 185 | 26.4 | 22.6–30.2 | 462 | 13.3 | 11.8–14.8 |
| 1 | 352 | 40.5 | 36.1–44.9 | 981 | 30.7 | 28.6–32.8 |
| ≥2 | 2735 | 77.7 | 75.7–79.6 | 7781 | 71.9 | 70.7–73.1 |
Abbreviations: CI, confidence interval